EPO Patent Bulletin - Biotech (C12N)
Wednesday, April 15, 2026
Roche Oligonucleotides for Paternal UBE3A Expression
The European Patent Office published patent application EP3798307A1 for F. Hoffmann-La Roche AG covering oligonucleotides designed to induce paternal UBE3A expression. The invention relates to nucleic acid therapeutics targeting UBE3A gene expression, with applications in treating genetic disorders. The patent application was filed under IPC classification C12N 15/113 and designates all 39 contracting states across the European Patent Convention.
Routine
Notice
Intellectual Property
Get daily alerts for EPO Patent Bulletin - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source details
Activity
Browse Categories
Agriculture & Food Safety
64
AI Regulation
3
Banking & Finance
292
Consumer Protection
44
Courts & Legal
361
Data Privacy & Cybersecurity
73
Defense & National Security
51
Education
19
Energy
100
Environment
86
Environmental Regulation
7
Financial Regulation
2
Government & Legislation
279
Healthcare
136
Housing
16
Immigration
8
Insurance
58
Labor & Employment
113
Legal & Judicial
2
Pharma & Drug Safety
104
Public Health
2
Securities & Markets
103
Securities Regulation
6
Tax
65
Telecom & Technology
47
Trade & Sanctions
135
Transportation
57
Get EPO Patent Bulletin - Biotech (C12N) alerts
We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.
You're subscribed!